<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Treatment of acromegaly
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Treatment of acromegaly
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Treatment of acromegaly
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Shlomo Melmed, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Laurence Katznelson, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Peter J Snyder, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kathryn A Martin, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Apr 28, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acromegaly is almost always caused by a somatotroph (growth hormone [GH]-secreting) adenoma of the pituitary gland and is associated with increased morbidity and mortality. As a result, almost all patients should be treated, even those who are asymptomatic and those in whom the disorder does not seem to be progressing. One exception is a patient with a short life expectancy who is not expected to live long enough to benefit from therapy.
        </p>
        <p>
         The treatment of acromegaly will be reviewed here. The clinical manifestations and diagnosis of acromegaly are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6633.html" rel="external">
          "Causes and clinical manifestations of acromegaly"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6635.html" rel="external">
          "Diagnosis of acromegaly"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          GOALS OF THERAPY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The goals of therapy in patients with acromegaly are to lower the serum insulin-like growth factor-1 (IGF-1) concentration to within the normal range for the patient's age and gender, control adenoma size and reduce mass effects, improve symptoms, and reverse metabolic abnormalities such as diabetes mellitus [
         <a href="#rid1">
          1
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6633.html" rel="external">
          "Causes and clinical manifestations of acromegaly", section on 'Metabolic'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In addition to lowering IGF-1, another biochemical goal is to lower the serum growth hormone (GH) concentration to &lt;1 mcg/L as measured by immunoradiometric or chemiluminescent assay, as this also correlates with control of acromegaly. [
         <a href="#rid2">
          2
         </a>
         ]. However, the IGF-1 criterion may be better since some patients who appear to have active disease clinically and by elevated IGF-1 concentration have serum GH values that suppress to &lt;1 mcg/L [
         <a href="#rid3">
          3,4
         </a>
         ]. Serum IGF-1 concentrations also correlate better than serum GH with insulin sensitivity in patients with acromegaly [
         <a href="#rid5">
          5
         </a>
         ]. (See
         <a class="local">
          'Biochemical outcomes'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         When serum GH and IGF-1 concentrations decline to normal [
         <a href="#rid6">
          6
         </a>
         ], the characteristic soft tissue overgrowth and related symptoms gradually recede and the metabolic abnormalities, such as diabetes mellitus, improve. In addition, life expectancy returns to that of the general population [
         <a href="#rid7">
          7,8
         </a>
         ]. However, bony abnormalities generally do not regress and joint symptoms persist. (See
         <a class="local">
          'Amelioration of symptoms'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Another goal of treatment is to alleviate symptoms due to the direct effects of the somatotroph adenoma (headaches, vision loss), without causing hypopituitarism.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H689545547">
         <span class="h1">
          OVERVIEW OF APPROACH
         </span>
         <span class="headingEndMark">
          —
         </span>
         A summary of treatment effects is provided in the table (
         <a class="graphic graphic_table graphicRef55079" href="/z/d/graphic/55079.html" rel="external">
          table 1
         </a>
         ). The choice of initial treatment depends upon the size and location of the adenoma, the presence of symptoms due to size (such as impairment of vision), and the patient's ability to undergo surgery (
         <a class="graphic graphic_algorithm graphicRef116165" href="/z/d/graphic/116165.html" rel="external">
          algorithm 1
         </a>
         ). The approach outlined here is similar to the Endocrine Society's 2014 Clinical Practice Guideline [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1122883082">
         <span class="h2">
          Transsphenoidal surgery
         </span>
         <span class="headingEndMark">
          —
         </span>
         For the majority of patients with acromegaly, we recommend transsphenoidal surgery as the initial therapy (
         <a class="graphic graphic_algorithm graphicRef116165" href="/z/d/graphic/116165.html" rel="external">
          algorithm 1
         </a>
         ). This includes patients with a microadenoma, a macroadenoma that appears to be fully resectable, or a macroadenoma causing impairment of vision. We also recommend that transsphenoidal surgery be performed by a neurosurgeon with considerable experience in pituitary surgery [
         <a href="#rid2">
          2
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/86683.html" rel="external">
          "Transsphenoidal surgery for pituitary adenomas and other sellar masses", section on 'Somatotroph adenomas (acromegaly)'
         </a>
         .)
        </p>
        <p>
         We suggest
         <strong>
          surgical debulking
         </strong>
         for patients with macroadenomas abutting or adjacent to the chiasm (followed by medical therapy) (
         <a class="graphic graphic_algorithm graphicRef116165" href="/z/d/graphic/116165.html" rel="external">
          algorithm 1
         </a>
         ). Medical treatment may be more effective after surgical debulking. (See
         <a class="local">
          'Somatostatin analogs'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3996894877">
         <span class="h3">
          Potential complications
         </span>
         <span class="headingEndMark">
          —
         </span>
         The perioperative mortality rate is less than 1 percent in patients with large, invasive adenomas and negligible in patients with smaller ones. Long-term deficiency of one or more pituitary hormones has been reported in up to 70 percent of patients [
         <a href="#rid8">
          8,9
         </a>
         ]. Patients treated with both surgery and radiation are particularly prone to develop pituitary hormonal deficiencies, including growth hormone (GH) deficiency [
         <a href="#rid10">
          10
         </a>
         ]. (See
         <a class="local">
          'Should GH deficiency be treated?'
         </a>
         below.)
        </p>
        <p>
         Other major complications of surgery occur in approximately 8 percent of patients. These include arginine vasopressin deficiency (AVP-D, previously called central diabetes insipidus) (2 percent), cerebrospinal fluid rhinorrhea (2 percent), and meningitis (2 percent) [
         <a href="#rid8">
          8,11
         </a>
         ]. All are more common in patients with macroadenomas.
        </p>
        <p>
         These complication rates reflect results from neurosurgeons with the most experience with transsphenoidal surgery. Rates with less experienced surgeons are much higher [
         <a href="#rid12">
          12,13
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2299947389">
         <span class="h3">
          Postoperative evaluation
         </span>
         <span class="headingEndMark">
          —
         </span>
         The early cure rate in patients with acromegaly is 80 to 90 percent for microadenomas and less than 50 percent for macroadenomas (see
         <a class="local">
          'Surgical cure rate'
         </a>
         below). We measure insulin-like growth factor-1 (IGF-1) levels and a random growth hormone (GH) approximately 12 weeks after surgery as it may take this long for IGF-1 to normalize; a decision can then be made whether adjuvant therapy should be initiated (
         <a class="graphic graphic_algorithm graphicRef116165" href="/z/d/graphic/116165.html" rel="external">
          algorithm 1
         </a>
         ). If a random GH is &gt;1 mcg/L, we remeasure GH after a glucose load; a post-glucose serum GH less than 1 mcg/L is consistent with control of acromegaly [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
         The early cure rate in patients with acromegaly is 80 to 90 percent for microadenomas and less than 50 percent for macroadenomas. (See
         <a class="local">
          'Biochemical outcomes'
         </a>
         below and
         <a class="local">
          'Surgical cure rate'
         </a>
         below.)
        </p>
        <p>
         We also suggest performing a pituitary magnetic resonance imaging (MRI) study at least 12 weeks after surgery to look for residual tumor and assess adjacent structures (
         <a class="graphic graphic_algorithm graphicRef116165" href="/z/d/graphic/116165.html" rel="external">
          algorithm 1
         </a>
         ). It is important to wait 12 weeks to allow for involution of gel foam and fat packing [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H172923319">
         <span class="h4">
          Normal IGF-1 and no residual tumor on MRI
         </span>
         <span class="headingEndMark">
          —
         </span>
         If transsphenoidal surgery results in normalization of serum insulin-like growth factor-1 (IGF-1) concentration and no evidence of residual tumor on magnetic resonance imaging (MRI), we suggest no further therapy. Long-term biochemical monitoring and imaging follow-up for these patients is described below. (See
         <a class="local">
          'Monitoring'
         </a>
         below.)
        </p>
        <p>
         The risk of recurrence is reviewed below. (See
         <a class="local">
          'Recurrence'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H322479576">
         <span class="h4">
          Patients with residual disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with residual disease (biochemically or on MRI) need additional treatment. This can include repeat surgery, medical therapy, and/or radiation therapy (
         <a class="graphic graphic_algorithm graphicRef116165" href="/z/d/graphic/116165.html" rel="external">
          algorithm 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H2122653175">
         <span class="h2">
          Additional therapy for residual disease
         </span>
        </p>
        <p class="headingAnchor" id="H1840267155">
         <span class="h3">
          Repeat surgery
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest repeat transsphenoidal surgery for patients with (
         <a class="graphic graphic_algorithm graphicRef116165" href="/z/d/graphic/116165.html" rel="external">
          algorithm 1
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Residual intrasellar mass that compresses vital structures after initial surgery
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Significant residual tumor in the sella that is resectable
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1627349177">
         <span class="h3">
          Medical therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with an abnormal serum IGF-1 and
         <strong>
          moderate
         </strong>
         symptoms of GH excess after transsphenoidal surgery, but who do not need repeat surgery, we suggest medical therapy (
         <a class="graphic graphic_algorithm graphicRef116165" href="/z/d/graphic/116165.html" rel="external">
          algorithm 1
         </a>
         ).
        </p>
        <p>
         For patients in whom transsphenoidal surgery does not result in normalization of serum IGF-1 concentration, particularly if they have
         <strong>
          moderate
         </strong>
         symptoms of GH excess, we suggest medical therapy with either a long-acting somatostatin analog or
         <a class="drug drug_general" data-topicid="10257" href="/z/d/drug information/10257.html" rel="external">
          pegvisomant
         </a>
         . We often use a somatostatin analog first because it tends to decrease the size of the adenoma, as well as its secretion of GH. Pegvisomant is another option for medical therapy in this setting. If a somatostatin analog is started first and treatment does not reduce IGF-1 levels to normal, we recommend adding pegvisomant, which blocks the action of GH. (See
         <a class="local">
          'Somatostatin analogs'
         </a>
         below and
         <a class="local">
          'Pegvisomant'
         </a>
         below.)
        </p>
        <p>
         In patients with only modest biochemical abnormalities, eg, GH concentrations &gt;1 mcg/L but &lt;1.3 mcg/L and mild symptoms of GH excess, we suggest a trial of
         <a class="drug drug_general" data-topicid="8600" href="/z/d/drug information/8600.html" rel="external">
          cabergoline
         </a>
         . (See
         <a class="local">
          'Dopamine agonists'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3394454788">
         <span class="h3">
          Stereotactic radiation therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         If medical therapy is ineffective or not tolerated, we suggest stereotactic radiation therapy (RT) (
         <a class="graphic graphic_algorithm graphicRef116165" href="/z/d/graphic/116165.html" rel="external">
          algorithm 1
         </a>
         ). Other indications for RT include (see
         <a class="local">
          'Radiation therapy'
         </a>
         below):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An adenoma increasing in size despite medical therapy (ie, somatostatin analog plus
         <a class="drug drug_general" data-topicid="10257" href="/z/d/drug information/10257.html" rel="external">
          pegvisomant
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Aggressive or atypical adenomas
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patient desire to avoid the cost and administration of long-term medical therapy
        </p>
        <p>
        </p>
        <p>
         The use of RT for the management of acromegaly is reviewed in detail below. (See
         <a class="local">
          'Radiation therapy'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3330384061">
         <span class="h2">
          Role of primary medical therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although we suggest transsphenoidal surgery as the initial step for most patients, we suggest medical therapy with a long-acting somatostatin analog as the initial step for patients who (
         <a class="graphic graphic_algorithm graphicRef116165" href="/z/d/graphic/116165.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid2">
          2
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Have an adenoma that does not appear to be fully resectable (eg, because of extensive cavernous sinus invasion but have no chiasmal compression)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Are poor surgical candidates or decline surgery
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Would benefit from preoperative medication to allow easier intubation by reducing severe laryngeal swelling and macroglossia and to improve obstructive apnea or cardiac dysfunction
        </p>
        <p>
        </p>
        <p>
         Following initial treatment, patients should be evaluated every three to four months by both clinical examination and measurement of serum IGF-1 concentration for at least the first year. Medication dose is titrated upwards as needed; if IGF-1 is not normalized at the maximum dose of somatostatin analog, alternative therapy should be considered. (See
         <a class="local">
          'Efficacy'
         </a>
         below.)
        </p>
        <p>
         Specifics about somatostatin analog therapy (dosing, impact on symptoms and adenoma size, and side effects) are reviewed below. (See
         <a class="local">
          'Somatostatin analogs'
         </a>
         below.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10257" href="/z/d/drug information/10257.html" rel="external">
          Pegvisomant
         </a>
         – Daily pegvisomant monotherapy may also be used as first-line therapy; its efficacy is determined by measuring IGF-1 and not GH. (See
         <a class="local">
          'Pegvisomant'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Combination therapy
         </strong>
         –
         <a class="drug drug_general" data-topicid="10257" href="/z/d/drug information/10257.html" rel="external">
          Pegvisomant
         </a>
         may be administered in combination with a somatostatin analog in patients in whom the IGF-1 response to the analog alone is suboptimal. If the combination is effective, it should be continued and monitored every six months. (See
         <a class="local">
          'Combination therapy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         If medical therapy is effective, it can be continued indefinitely.
        </p>
        <p class="headingAnchor" id="H73169474">
         <span class="h2">
          Long-term management
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several steps are involved in the long-term management of patients with acromegaly.
        </p>
        <p class="headingAnchor" id="H457070198">
         <span class="h3">
          Monitoring
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical and biochemical
         </strong>
         – Following initial treatment, patients should be evaluated every three to four months by both clinical examination and measurement of serum IGF-1 levels.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Following initial treatment of acromegaly, whether surgery or medication, IGF-1 should be measured in two to three months. It should not be measured sooner, because of the long half-life of IGF-1. An elevated level suggests that the treatment has not been sufficient. If the IGF-1 level is normal after the initial treatment, it should be measured again in six months and then annually.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If IGF-1 levels are normal, measuring random GH or post-oral glucose tolerance test (OGTT) nadir GH levels may not add helpful information. Medical therapy dose adjustments should be made using the IGF-1 levels. The Endocrine Society guidelines suggest that an age-normalized serum IGF-1 and a random GH &lt;1 mcg/L should both be therapeutic goals as they correlate with control of acromegaly [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients who are being treated with a medication should have the dose adjusted as needed [
         <a href="#rid14">
          14
         </a>
         ]. If normal IGF-1 values are not achieved, alternative therapy should be considered. In patients well controlled on medical therapy, we suggest biochemical testing (serum GH, IGF-1) every six months.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Imaging
         </strong>
         – MRI should be repeated 12 weeks after surgery and then yearly for the first several years after initial treatment and less often thereafter. Visual field assessment is indicated for patients whose adenomas threaten the optic chiasm [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Systemic evaluation
         </strong>
         – Acromegaly appears to be associated with an excess risk of colonic polyps. Based upon these observations, we suggest that colonoscopy be performed at baseline and then every five years thereafter in patients in those found to have a polyp or those with persistently elevated IGF-1 levels and every 10 years in those without polyps and with normal IGF-1 levels [
         <a href="#rid2">
          2
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6633.html" rel="external">
          "Causes and clinical manifestations of acromegaly", section on 'Other tumors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Comprehensive cardiovascular evaluation should be performed regularly, and hypertension and heart failure should be treated [
         <a href="#rid2">
          2
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6633.html" rel="external">
          "Causes and clinical manifestations of acromegaly", section on 'Cardiovascular disease'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H56212924">
         <span class="h4">
          Biochemical outcomes
         </span>
         <span class="headingEndMark">
          —
         </span>
         When transsphenoidal surgery is performed by the
         <strong>
          most experienced
         </strong>
         pituitary neurosurgeons, GH secretion falls to normal in approximately 80 to 90 percent of patients with microadenomas (less than 10 mm in diameter) and pituitary secretion of other hormones is preserved [
         <a href="#rid7">
          7,9,15
         </a>
         ]. The success rate is lower in patients with macroadenomas and/or higher preoperative serum GH concentrations [
         <a href="#rid9">
          9,11,15,16
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Time course
         </strong>
         – If surgery is successful, serum GH concentrations typically fall to normal within one to two hours, depending upon the degree of elevation. Serum IGF-1 concentrations fall more slowly, from 7 to 10 days to several months [
         <a href="#rid17">
          17
         </a>
         ]. There is a rapid diuresis, and soft-tissue swelling and hyperglycemia can diminish remarkably in a few days. Vision, if impaired, and headaches can also improve in days. Sleep apnea [
         <a href="#rid18">
          18
         </a>
         ] and cartilaginous overgrowth also improve but often persist [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3315970343">
         <span class="h4">
          Amelioration of symptoms
         </span>
         <span class="headingEndMark">
          —
         </span>
         When effective control of GH hypersecretion is achieved, serum GH and IGF-1 concentrations decline to normal [
         <a href="#rid6">
          6
         </a>
         ], the characteristic soft tissue overgrowth and related symptoms gradually recede, and the metabolic abnormalities (such as diabetes mellitus) and quality-of-life measures improve [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p>
         Sleep apnea, tissue swelling, headache, and arthralgias resolve or improve in approximately 70 percent of patients controlled on medical therapy. Most patients recover from obstructive sleep apnea after surgical or medical control of the growth hormone excess [
         <a href="#rid21">
          21
         </a>
         ]. Mortality outcomes appear to be more favorable with rigorous biochemical control.
        </p>
        <p>
         Skeletal, jaw, and joint changes are not reversible. This was illustrated in a study of 118 patients with acromegaly who were in long-term remission, as judged by serum normal IGF-1 concentration; 77 percent reported joint symptoms [
         <a href="#rid22">
          22
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6633.html" rel="external">
          "Causes and clinical manifestations of acromegaly", section on 'Bone and joints'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4236941880">
         <span class="h3">
          Should GH deficiency be treated?
         </span>
         <span class="headingEndMark">
          —
         </span>
         We do not suggest the routine use of growth hormone (GH) therapy in patients with acromegaly who develop GH deficiency, as available data are conflicting.
        </p>
        <p>
         It is estimated that 50 to 70 percent of patients with acromegaly treated with surgery alone or surgery combined with RT develop GH deficiency [
         <a href="#rid10">
          10
         </a>
         ], a complication that is associated with a decreased quality of life [
         <a href="#rid23">
          23
         </a>
         ]. However, the impact of GH therapy in those who develop GH deficiency is still unclear.
        </p>
        <p>
         In one trial, patients with cured acromegaly who developed GH deficiency had improved body composition (decrease in total body fat mass and abdominal fat) with GH therapy compared with placebo [
         <a href="#rid24">
          24
         </a>
         ]. In contrast, a second trial reported an increase in vascular events after two years of GH therapy in adults with GH deficiency previously treated for acromegaly [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3894128423">
         <span class="h2">
          Pregnancy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most women with untreated acromegaly have menstrual dysfunction and infertility due to one or more of the following [
         <a href="#rid26">
          26
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Decreased secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) due to compression of gonadotroph cells by a macroadenoma
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hyperprolactinemia due to pituitary stalk compression
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hyperprolactinemia due to a mixed GH-prolactin secreting adenoma
        </p>
        <p>
        </p>
        <p>
         We suggest the following approach to managing women planning pregnancy and pregnant/postpartum women with acromegaly:
        </p>
        <p class="headingAnchor" id="H139399126">
         <span class="h3">
          Preconception
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The serum GH and IGF-1 concentrations should be as tightly controlled as possible in women with known acromegaly before attempting conception to minimize the risk of gestational diabetes mellitus (GDM) and gestation hypertension [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Somatostatin analogs should be discontinued two months and
         <a class="drug drug_general" data-topicid="10257" href="/z/d/drug information/10257.html" rel="external">
          pegvisomant
         </a>
         one month prior to trying to conceive.
        </p>
        <p class="bulletIndent1">
         Short-acting
         <a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">
          octreotide
         </a>
         may be used as necessary to control signs and symptoms of GH excess until conception [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1888685346">
         <span class="h3">
          During pregnancy/postpartum
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         During pregnancy, medical therapy should be withheld. Short-acting
         <a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">
          octreotide
         </a>
         can be used, but only for control of headache and adenoma size [
         <a href="#rid2">
          2
         </a>
         ]. Most data suggest that somatostatin analog administration during pregnancy has not been associated with adverse events [
         <a href="#rid27">
          27-29
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We suggest against routine measurement of either serum GH or IGF-1 in pregnant patients. GH assays recognize both normal and placental variants of GH in gravid women. GH stimulates production of IGF-1 and may raise IGF-1 levels above the age-adjusted normal range [
         <a href="#rid30">
          30,31
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The majority of small pituitary adenomas do not grow during pregnancy [
         <a href="#rid32">
          32
         </a>
         ]. For women who have macroadenomas, we suggest monitoring visual fields during each trimester of pregnancy. If visual fields show new defects, MRI should be performed. If vision is newly impaired and growth of the adenoma is the likely cause, surgery may be necessary.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Breastfeeding is a reasonable option for women who do not require treatment hormone immediately after delivery.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3514861103">
         <span class="h3">
          Outcomes
         </span>
         <span class="headingEndMark">
          —
         </span>
         When women with acromegaly do conceive, the majority appear to have uncomplicated pregnancies, although data are limited [
         <a href="#rid28">
          28
         </a>
         ]. In one retrospective, multicenter study of 59 pregnancies in 46 women with GH-secreting pituitary macroadenomas or less often microadenomas, 43 of the 46 women had previously been treated with surgery or radiotherapy [
         <a href="#rid32">
          32
         </a>
         ]. Prior to conception, GH and IGF-1 hypersecretion was controlled in 23 (40 percent) and uncontrolled in 34 (60 percent) patients. Medical therapy was discontinued in early pregnancy in all but four women. The following findings were noted:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pregnancy was uneventful for most women; the 59 pregnancies resulted in 64 healthy babies.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         No major neonatal malformations were encountered.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Four women continued somatostatin analog therapy during pregnancy, all gave birth to a small for gestational age infant.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         GDM and gestational hypertension, which developed in 7 and 14 percent of pregnancies, respectively, was more common in women with active or uncontrolled acromegaly. Among those who had postpartum MRI imaging data available, only 2 of 22 (7 percent) showed an increase in pituitary tumor size.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Seventeen women breastfed with no complications.
        </p>
        <p>
        </p>
        <p>
         In a second report of 13 pregnancies in women with acromegaly, similar findings were seen; 10 of 13 received no medical therapy during the pregnancy. There were no pregnancy complications and no congenital malformations, but one of the three infants whose mother had received medical therapy (somatostatin analog) had low birth weight [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1637140032">
         <span class="h1">
          REVIEW OF TREATMENT OPTIONS
         </span>
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Transsphenoidal surgery
         </span>
         <span class="headingEndMark">
          —
         </span>
         Selective transsphenoidal surgical resection is the treatment of choice for patients with somatotroph adenomas that are small, large but still resectable, or large and cause visual impairment (
         <a class="graphic graphic_algorithm graphicRef116165" href="/z/d/graphic/116165.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid11">
          11,15,33,34
         </a>
         ]. Surgery may also be considered for large adenomas that are not entirely accessible surgically (eg, those with cavernous sinus extension), with the goal of removing a sufficient mass of tissue to increase the likelihood that somatostatin analog treatment will be effective postoperatively. Some authorities recommend somatostatin analog treatment preoperatively, although the studies do not conclusively support this approach [
         <a href="#rid35">
          35
         </a>
         ]. (See
         <a class="local">
          'Role of primary medical therapy'
         </a>
         above.)
        </p>
        <p>
         Transsphenoidal surgery has been widely employed to treat pituitary adenomas, including somatotroph adenomas, since the 1970s. The approach during much of this time has been sublabial and transseptal using an operating microscope. During the past decade, an endoscopic approach has gained acceptance because it provides superior visualization of the suprasellar compartment and cavernous sinus walls. Studies describing patients treated for acromegaly by endoscopic surgery suggest that although this approach is promising, outcomes for acromegaly are not definitively superior to previously published microscopic series [
         <a href="#rid36">
          36,37
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/86683.html" rel="external">
          "Transsphenoidal surgery for pituitary adenomas and other sellar masses"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h3">
          Surgical cure rate
         </span>
         <span class="headingEndMark">
          —
         </span>
         Accurate interpretation and comparison of studies reporting surgical cure rates in patients with acromegaly is difficult since both the duration of follow-up and the biochemical criteria for cure have varied. The current goal is a serum insulin-like growth factor-1 (IGF-1) concentration normal for age and gender and a serum growth hormone (GH) concentration less than 1 mcg/L or lower by immunoradiometric or chemiluminescent assay.
        </p>
        <p>
         The cure rate using these criteria is illustrated in a report of 57 patients followed for at least 12 months postoperatively [
         <a href="#rid38">
          38
         </a>
         ]. Surgical remission rates were 70, 67, and 61 percent, as assessed by normal serum IGF-1, random serum GH concentration &lt;2.5 mcg/L, and glucose-suppressed GH concentration &lt;1 mcg/L, respectively [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p>
         Although summarizing surgical cure rates across studies is difficult for the reasons noted above, the early cure rate in patients with acromegaly is 80 to 90 percent for microadenomas and less than 50 percent for macroadenomas [
         <a href="#rid3">
          3,7-9,11,15,16,38,39
         </a>
         ].
        </p>
        <p>
         Complications are reviewed above. (See
         <a class="local">
          'Potential complications'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h3">
          Recurrence
         </span>
         <span class="headingEndMark">
          —
         </span>
         Studies with several years of follow-up provide information on recurrence rates. Approximately 3 to 10 percent of patients in whom the operation is initially successful, as determined by normal basal and normal post-oral glucose tolerance test (OGTT) serum GH concentrations, have a recurrence several years or more after surgery, probably due to incomplete adenoma resection [
         <a href="#rid7">
          7-9,11,38
         </a>
         ]. Higher rates of recurrence (eg, 19 percent) have been reported in series in which initial surgical cure rates were lower than those cited above [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
         Even if the nadir of the serum GH concentrations after an OGTT is only slightly above the target values, the risk of recurrence is greater, as illustrated by a study of 77 patients with apparent biochemical remission after surgery (normal serum IGF-1 concentrations) [
         <a href="#rid40">
          40
         </a>
         ]. The patients were stratified according to the nadir serum GH concentration after an OGTT. Fifty patients (group 1) were considered to have a normal nadir GH (&lt;0.14 mcg/L, based upon mean levels in normal, healthy controls) and 26 had an abnormal nadir (&gt;0.14 mcg/L, group 2). At a mean follow-up of 3.2 years, the following results were seen in group 2 when compared with group 1 patients:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Higher mean hourly GH concentrations (based upon hourly GH sampling for eight hours)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Higher rate of recurrence, defined as an elevated serum IGF-1 concentration, in patients for whom data were available (5 of 19 versus 0 of 49)
        </p>
        <p>
        </p>
        <p>
         Thus, patients with even subtle abnormalities in post-suppression GH levels may have a greater risk of recurrence.
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Medical therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several medications are available for treating acromegaly, including some that inhibit GH secretion and one that inhibits its action. Pharmacologic treatment is used when surgery alone has not reduced serum GH and IGF-1 to normal.
        </p>
        <p>
         Patients for whom a medication can be considered as primary therapy include those who have unacceptable surgical risk, refuse surgery, or have adenomas that are unlikely to be cured surgically [
         <a href="#rid1">
          1,41
         </a>
         ]. (See
         <a class="local">
          'Role of primary medical therapy'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h3">
          Somatostatin analogs
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">
          Octreotide
         </a>
         and
         <a class="drug drug_general" data-topicid="10184" href="/z/d/drug information/10184.html" rel="external">
          lanreotide
         </a>
         are analogs of somatostatin (GH-inhibitory hormone) that inhibit GH secretion more effectively than native somatostatin because of their greater potency and longer plasma half-life (two hours versus two minutes). Somatostatin analogs inhibit GH secretion by binding to specific receptors for somatostatin and its analogs [
         <a href="#rid42">
          42
         </a>
         ]. Their effect is greater when the number of receptors is high [
         <a href="#rid43">
          43,44
         </a>
         ]; repetitive administration does not result in desensitization or loss of therapeutic efficacy [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H745767703">
         <span class="h4">
          Octreotide and lanreotide
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">
          Octreotide
         </a>
         and
         <a class="drug drug_general" data-topicid="10184" href="/z/d/drug information/10184.html" rel="external">
          lanreotide
         </a>
         also cause pituitary adenoma shrinkage in some patients. The mechanism of the shrinkage remains unclear. In a study of tissue samples from 32 surgically resected somatotroph macroadenomas, the mean growth fraction of adenomas exposed to octreotide was 83 percent less than those not exposed [
         <a href="#rid46">
          46
         </a>
         ]. However, in another report, octreotide exhibited an antiproliferative effect but no effect on the apoptotic index [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1516345258">
         <span class="h5">
          Dose and administration
         </span>
         <span class="headingEndMark">
          —
         </span>
         Two somatostatin analogs,
         <a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">
          octreotide
         </a>
         and
         <a class="drug drug_general" data-topicid="10184" href="/z/d/drug information/10184.html" rel="external">
          lanreotide
         </a>
         , are widely available. The long-acting form of octreotide is given as an intramuscular injection once a month. The initial dose is 20 mg once a month. If the serum IGF-1 concentration does not decrease to normal within two months, the dose can be increased to 30 mg and then to 40 mg a month.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="10184" href="/z/d/drug information/10184.html" rel="external">
          Lanreotide
         </a>
         is available in different forms in different countries. A deep subcutaneous form (lanreotide autogel or depot) is given as 60 to 120 mg every four to six weeks [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p>
         In a study of 30 patients with a partial response to a somatostatin analog, use of
         <strong>
          high dose
         </strong>
         (180 mg/28 days) or
         <strong>
          high frequency
         </strong>
         (120 mg/21 days) both resulted in normalization of IGF-1 in approximately 30 percent of subjects [
         <a href="#rid49">
          49
         </a>
         ]. These regimens were well tolerated, and adverse events were similar between the groups. In a prior study, use of a high-dose, long-acting
         <a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">
          octreotide
         </a>
         preparation (60 mg/28 days) resulted in normalization of IGF-1 in 36 percent of partial responders [
         <a href="#rid50">
          50
         </a>
         ]. Such regimen may be considered in such subjects.
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h5">
          Efficacy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Efficacy should be judged by normalization of the serum GH and IGF-1 concentrations, which should eventually be followed by regression of the soft tissue manifestations of acromegaly and by shrinkage of adenoma size. The two once-monthly preparations,
         <a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">
          octreotide
         </a>
         long-acting release (LAR) and
         <a class="drug drug_general" data-topicid="10184" href="/z/d/drug information/10184.html" rel="external">
          lanreotide
         </a>
         (autogel or depot) appear to be equivalent for control of biochemical markers and symptoms [
         <a href="#rid51">
          51
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Predictors of response
         </strong>
         – Tumor subtypes may be a predictor of response to somatostatin analog therapy. The densely granulated tumors are typically smaller and more active (produce more GH) and respond well to somatostatin analogs [
         <a href="#rid52">
          52,53
         </a>
         ]. In contrast, the sparsely granulated subtype tumors tend to be larger, more common in females and in younger patients, more invasive, and are relatively less responsive to somatostatin analogs.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A hypointense T2 signal on magnetic resonance imaging (MRI) also appears to be associated with a better response to somatostatin analog therapy when given either pre- [
         <a href="#rid54">
          54
         </a>
         ] or postoperatively [
         <a href="#rid55">
          55
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Biochemical improvement
         </strong>
         – Normalization of serum IGF-1 concentration with somatostatin analogs occurs in 40 to 75 percent of patients. The success rate varies markedly with study design, ranging in two reports from 38 percent in patients who were not preselected for responsiveness (
         <a class="graphic graphic_figure graphicRef62473" href="/z/d/graphic/62473.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid56">
          56
         </a>
         ] to a mean of 66 percent in a review of several studies, most of which included patients who had been preselected for responsiveness to the short-acting form [
         <a href="#rid57">
          57
         </a>
         ]. Combined therapy with
         <a class="drug drug_general" data-topicid="8600" href="/z/d/drug information/8600.html" rel="external">
          cabergoline
         </a>
         and a somatostatin analog may be effective when either alone is not [
         <a href="#rid58">
          58
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Improvement in symptoms
         </strong>
         – A somewhat greater percentage of patients appear to experience improvement in symptoms with somatostatin analogs than exhibit IGF-1 normalization, presumably because even a partial decrease in GH results in some degree of symptomatic improvement [
         <a href="#rid59">
          59
         </a>
         ]. (See
         <a class="local">
          'Amelioration of symptoms'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Successful therapy is associated with an improvement in several signs and symptoms during the year following a decrease in biochemical parameters (see
         <a class="local">
          'Amelioration of symptoms'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Soft-tissue swelling, carpal tunnel syndrome, and snoring [
         <a href="#rid57">
          57
         </a>
         ]
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Sleep apnea [
         <a href="#rid60">
          60,61
         </a>
         ]
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Left ventricular mass and left ventricular function [
         <a href="#rid62">
          62-64
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adenoma size
         </strong>
         – Somatostatin analog therapy leads to a reduction in adenoma size of approximately 20 to 50 percent in 30 percent of patients (
         <a class="graphic graphic_figure graphicRef65053" href="/z/d/graphic/65053.html" rel="external">
          figure 2
         </a>
         and
         <a class="graphic graphic_diagnosticimage graphicRef64387" href="/z/d/graphic/64387.html" rel="external">
          image 1
         </a>
         ) [
         <a href="#rid57">
          57
         </a>
         ]. In a 2005 systematic review of patients with acromegaly receiving a somatostatin analog as primary medical therapy (before or as an alternative to surgery and radiotherapy), approximately 37 percent experienced a significant reduction in adenoma size (mean 19 percent) [
         <a href="#rid65">
          65
         </a>
         ]. In a subsequent study of 99 patients who received somatostatin analogs as primary therapy, 45 percent had normalization of serum IGF-1 concentration, and 44 percent had a &gt;50 percent reduction of adenoma size [
         <a href="#rid66">
          66
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h5">
          Side effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         Somatostatin analogs are usually well tolerated. Approximately one-third of patients have nausea, abdominal discomfort, bloating, loose stools, and fat malabsorption during the first several weeks of therapy, after which the symptoms usually subside spontaneously with continued use [
         <a href="#rid67">
          67
         </a>
         ].
        </p>
        <p>
         Somatostatin analogs are associated with an increased risk of gallstone disease. Up to 56 percent of patients develop asymptomatic cholesterol gallstones or sludge during the first 18 months of therapy [
         <a href="#rid57">
          57,68
         </a>
         ]. However, we do not suggest routine abdominal ultrasound monitoring. We suggest ultrasound only if the patient develops signs and symptoms suggestive of gallstone disease [
         <a href="#rid2">
          2
         </a>
         ]. Less common side effects include hair loss, constipation, and bradycardia.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">
          Octreotide
         </a>
         and
         <a class="drug drug_general" data-topicid="10184" href="/z/d/drug information/10184.html" rel="external">
          lanreotide
         </a>
         transiently inhibit insulin secretion, but their clinical impact on glucose homeostasis is minimal. This was illustrated by a meta-analysis of 18 trials in patients receiving these analogs for acromegaly. Fasting insulin concentrations were significantly reduced and glucose levels were slightly higher on an OGTT, but there were no significant changes in fasting glucose or glycated hemoglobin (A1C) values [
         <a href="#rid69">
          69
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H20635974">
         <span class="h4">
          Pasireotide
         </span>
         <span class="headingEndMark">
          —
         </span>
         The somatostatin analog
         <a class="drug drug_general" data-topicid="87457" href="/z/d/drug information/87457.html" rel="external">
          pasireotide
         </a>
         is also effective in some patients with acromegaly and is approved for its treatment, but it frequently causes or worsens hyperglycemia.
        </p>
        <p>
         In a 12-month trial of 358 patients with acromegaly (with no prior medical therapy) receiving
         <a class="drug drug_general" data-topicid="87457" href="/z/d/drug information/87457.html" rel="external">
          pasireotide
         </a>
         LAR (40 mg once/month by intramuscular injection) or
         <a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">
          octreotide
         </a>
         LAR (20 mg/month intramuscular injection), biochemical control was achieved in more patients receiving pasireotide when compared with octreotide (31.3 versus 19.2 percent, respectively) [
         <a href="#rid70">
          70
         </a>
         ]. Submaximal dosing of octreotide may have contributed to its lower rate of biochemical control. Similar to what has been observed in patients with Cushing's disease, hyperglycemia (often requiring insulin treatment) was more common with pasireotide LAR than octreotide LAR (57.3 versus 21.7 percent). (See
         <a class="medical medical_review" href="/z/d/html/119.html" rel="external">
          "Medical therapy of hypercortisolism (Cushing's syndrome)", section on 'Pasireotide'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H96152322">
         <span class="h4">
          Oral octreotide
         </span>
         <span class="headingEndMark">
          —
         </span>
         An oral formulation of
         <a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">
          octreotide
         </a>
         (delayed-release capsules) based on a transient permeability enhancer that enables bioactive gastrointestinal absorption has been approved for use for the management of acromegaly [
         <a href="#rid71">
          71
         </a>
         ]. This agent is indicated for long-term maintenance therapy in patients with acromegaly who have responded to and tolerated treatment with either octreotide or
         <a class="drug drug_general" data-topicid="10184" href="/z/d/drug information/10184.html" rel="external">
          lanreotide
         </a>
         .
        </p>
        <p>
         It appears to be effective in some patients with acromegaly, but perhaps less so than long-acting injectable preparations. In an open-label study of 155 patients previously controlled on injectable somatostatin analogs, patients were switched to oral
         <a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">
          octreotide
         </a>
         capsules (40 mg/day in two divided doses, increased up to 80 mg/day as needed) [
         <a href="#rid72">
          72
         </a>
         ]. Sixty-five percent (98 of 151) of the intent-to-treat population achieved the primary endpoint of GH/IGF-1 control, compared with 91 percent (138 of 151) while taking long-acting injectable somatostatin analogs; among the 91 patients who entered a subsequent fixed-dose phase (40 to 80 mg daily), 85 percent (77 of 91) sustained control for up to a total of 13 months. The adverse event profile was similar to that observed for injectable somatostatin analogs.
        </p>
        <p class="headingAnchor" id="H731275173">
         <span class="h3">
          Pegvisomant
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="10257" href="/z/d/drug information/10257.html" rel="external">
          Pegvisomant
         </a>
         is a GH receptor antagonist that is a mutated GH molecule to which polymers have been attached at several sites to prolong its half-life [
         <a href="#rid73">
          73
         </a>
         ]. The mutation results in increased affinity to site 1 on the GH receptor but decreased binding to site 2. As a result, pegvisomant blocks native GH from binding but does not activate the intracellular signaling that mediates its action.
        </p>
        <p>
         Patients receiving
         <a class="drug drug_general" data-topicid="10257" href="/z/d/drug information/10257.html" rel="external">
          pegvisomant
         </a>
         should be monitored by measuring IGF-1 levels (but not GH levels), as well as serial MRIs, to assure that there is no continued tumor growth. In addition, liver function tests (LFTs) should be measured every six months, and if more than threefold elevated, the drug should be discontinued.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="10257" href="/z/d/drug information/10257.html" rel="external">
          Pegvisomant
         </a>
         is administered as a daily, subcutaneous injection. The initial daily dose is 10 mg. The serum IGF-1 concentration should be measured every four to six weeks and the dose adjusted, in 5 mg increments, to a maximum of 30 mg/day, to keep the serum IGF-1 within the normal range. Preliminary data suggest that alternate-day dosing may be effective in some patients [
         <a href="#rid74">
          74
         </a>
         ].
        </p>
        <p>
         A number of factors affect the dose required to normalize serum IGF-1 concentrations [
         <a href="#rid75">
          75
         </a>
         ]. Higher doses are needed the higher the baseline IGF-1 concentration and the greater the patient's weight, and women need higher doses than men for the same weight. Lower doses are needed for patients who have had radiation therapy (RT) for comparable IGF-1 values.
        </p>
        <p>
         Serum GH cannot be used to monitor the effectiveness of treatment, since
         <a class="drug drug_general" data-topicid="10257" href="/z/d/drug information/10257.html" rel="external">
          pegvisomant
         </a>
         inhibits the action of GH rather than its secretion.
        </p>
        <p class="headingAnchor" id="H4108131952">
         <span class="h4">
          Efficacy
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="10257" href="/z/d/drug information/10257.html" rel="external">
          Pegvisomant
         </a>
         is an effective therapy for lowering serum IGF-1 concentrations. In a 12-week study of 112 patients, most of whom had received other treatment, pegvisomant doses of 10, 15, or 20 mg daily resulted in dose-dependent reductions in serum IGF-1 concentrations, as well as in fatigue, soft-tissue swelling, perspiration, and ring size, compared with no changes in the placebo group [
         <a href="#rid76">
          76
         </a>
         ].
        </p>
        <p>
         When the same patients and 48 others were treated with up to 40 mg/day for an average of 425 days, 97 percent of those treated for 12 months or more achieved normal IGF-1 concentrations (
         <a class="graphic graphic_figure graphicRef66653" href="/z/d/graphic/66653.html" rel="external">
          figure 3
         </a>
         ). This is a much higher response rate for IGF-1 levels than achieved by any other therapy. At the same time, the serum GH concentration increased by a mean 12.5 mcg/L [
         <a href="#rid77">
          77
         </a>
         ].
        </p>
        <p>
         The results in clinical practice may not be as good as in clinical trials. In an international surveillance registry of 1288 patients with acromegaly receiving
         <a class="drug drug_general" data-topicid="10257" href="/z/d/drug information/10257.html" rel="external">
          pegvisomant
         </a>
         for an average of 3.7 years [
         <a href="#rid78">
          78
         </a>
         ], only 56.6 percent of subjects had normal IGF-1 concentrations one year after beginning pegvisomant.
        </p>
        <p>
         Because
         <a class="drug drug_general" data-topicid="10257" href="/z/d/drug information/10257.html" rel="external">
          pegvisomant
         </a>
         does not inhibit GH secretion and its use is associated with an increase in the serum GH concentration, somatotroph adenoma size presumably could continue to grow during its use. However, this appears to be uncommon, as illustrated by the surveillance registry study cited above [
         <a href="#rid78">
          78
         </a>
         ]. In 30 of 936 patients (3.2 percent) for whom MRI data were available, an increase in adenoma size was noted in an average 2.1 years of follow-up. Based upon such observations, patients receiving pegvisomant should have adenoma size assessed by MRI at least once a year [
         <a href="#rid79">
          79
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2648001465">
         <span class="h4">
          Safety
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the registry study noted above [
         <a href="#rid78">
          78
         </a>
         ], 30 subjects (2.5 percent) developed elevated liver enzymes greater than three times the upper limit of normal. In the 23 subjects for whom follow-up data were available, liver enzymes returned to normal after decrease or discontinuation of
         <a class="drug drug_general" data-topicid="10257" href="/z/d/drug information/10257.html" rel="external">
          pegvisomant
         </a>
         . There were no reports of liver failure [
         <a href="#rid78">
          78
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="10257" href="/z/d/drug information/10257.html" rel="external">
          Pegvisomant
         </a>
         should therefore not be prescribed to patients who have clearly abnormal liver function, and patients who are treated should be monitored by LFTs once a month during the first six months of treatment and every four to six months thereafter. Pegvisomant has also been shown to be associated with lipohypertrophy both at the injection site and at distant sites [
         <a href="#rid80">
          80,81
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2205368691">
         <span class="h3">
          Combination therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The combination of a long-acting somatostatin analog and
         <a class="drug drug_general" data-topicid="10257" href="/z/d/drug information/10257.html" rel="external">
          pegvisomant
         </a>
         , in a few reports [
         <a href="#rid82">
          82-84
         </a>
         ], decreased serum IGF-1 concentrations to normal in a majority of patients, but the combination was not clearly better than pegvisomant alone. For example, in 27 patients who were suboptimally controlled while taking long-acting
         <a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">
          octreotide
         </a>
         alone, randomization to either the combination of the analog combined with pegvisomant or pegvisomant alone led to normalization of IGF-1 in 62 and 56 percent, respectively [
         <a href="#rid83">
          83
         </a>
         ]. The combination, however, seems to be associated with a greater incidence of transaminase elevations than either alone, as high as 38 percent [
         <a href="#rid82">
          82-84
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h3">
          Dopamine agonists
         </span>
         <span class="headingEndMark">
          —
         </span>
         Dopamine agonists, especially
         <a class="drug drug_general" data-topicid="8600" href="/z/d/drug information/8600.html" rel="external">
          cabergoline
         </a>
         , may inhibit GH secretion in some patients with acromegaly but do not work as well as somatostatin analogs. However, their oral route of administration is an advantage over the other treatments, which are administered parenterally. Cabergoline is the most effective dopamine agonist for the adjuvant management of acromegaly and is therefore the drug of choice in this category [
         <a href="#rid85">
          85
         </a>
         ].
        </p>
        <p>
         We currently suggest a trial of
         <a class="drug drug_general" data-topicid="8600" href="/z/d/drug information/8600.html" rel="external">
          cabergoline
         </a>
         , rather than somatostatin analogs or
         <a class="drug drug_general" data-topicid="10257" href="/z/d/drug information/10257.html" rel="external">
          pegvisomant
         </a>
         , in patients with modest biochemical abnormalities, eg, GH concentrations &gt;1 mcg/L but &lt;1.3 mcg/L and only mild symptoms of GH excess.
        </p>
        <p>
         We also suggest
         <a class="drug drug_general" data-topicid="8600" href="/z/d/drug information/8600.html" rel="external">
          cabergoline
         </a>
         in combination with a somatostatin analog in patients in whom somatostatin analog treatment alone has reduced serum IGF-1 concentrations almost to normal. This combination offers the possibility of reducing the IGF-1 further to mid-normal with the addition of a relatively inexpensive medication administered orally. (See
         <a class="local">
          'Medical therapy'
         </a>
         above.)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="8600" href="/z/d/drug information/8600.html" rel="external">
          Cabergoline
         </a>
         could also be tried as primary therapy in the occasional patient who has only a mild elevation of IGF-1 and a small adenoma, is not a good candidate for surgery, and refuses monthly injections of a somatostatin analog.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8600" href="/z/d/drug information/8600.html" rel="external">
          Cabergoline
         </a>
         <strong>
          dosing
         </strong>
         – The initial dose of cabergoline should be 0.5 mg once a week or 0.25 mg twice a week. The dose should be increased, if necessary, to 1 mg twice a week. Higher doses are not likely to decrease GH further [
         <a href="#rid86">
          86
         </a>
         ]. The presence of hyperprolactinemia does not consistently predict GH and IGF-1 response.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a meta-analysis of 15 studies of
         <a class="drug drug_general" data-topicid="8600" href="/z/d/drug information/8600.html" rel="external">
          cabergoline
         </a>
         therapy in 227 patients with acromegaly, cabergoline achieved normal serum IGF-1 levels in 51 of 149 patients (34 percent) [
         <a href="#rid85">
          85
         </a>
         ]. In studies where cabergoline was added to a somatostatin analog, 40 of 77 (52 percent) achieved normal IGF-1 levels. However, these results should be interpreted with caution as some of the studies included in the meta-analysis included poorly defined patient groups and non-rigorous IGF-1 assays.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Side effects
         </strong>
         – The most common side effects of
         <a class="drug drug_general" data-topicid="8600" href="/z/d/drug information/8600.html" rel="external">
          cabergoline
         </a>
         are nausea, light headedness, and mental fogginess. Less common are nasal stuffiness, depression, and constipation. The high doses of cabergoline used in Parkinson disease have been associated with valvular heart disease, but the lower doses used for lactotroph adenomas have not. (See
         <a class="medical medical_review" href="/z/d/html/6630.html" rel="external">
          "Management of hyperprolactinemia", section on 'Valvular heart disease'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h2">
          Radiation therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         RT is effective in reducing the size of somatotroph adenomas and decreasing GH and IGF-1 concentrations, often to normal, but because the decreases in GH and IGF-1 usually take years to occur, we suggest its use primarily for patients whose disease is not controlled by surgery or medical therapy (
         <a class="graphic graphic_algorithm graphicRef116165" href="/z/d/graphic/116165.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid87">
          87
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H195816248">
         <span class="h3">
          Types of radiation
         </span>
         <span class="headingEndMark">
          —
         </span>
         The types of radiation therapy for pituitary adenomas, radiation delivery systems, and their efficacy and side effects are reviewed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/86684.html" rel="external">
          "Radiation therapy of pituitary adenomas"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Stereotactic radiosurgery (SRS)
         </strong>
         – Radiation can be administered as a single dose (often called "stereotactic radiosurgery," or SRS, although there is no surgery), by linear accelerator, gamma radiation, or protons. It has the advantage of patient convenience and possibly faster control of hormonal hypersecretion [
         <a href="#rid87">
          87
         </a>
         ]. Gamma radiation has been available more widely than the other forms of single-dose radiation (protons and x-radiation from a linear accelerator), so more data are available about it. The most commonly used stereotactic method used is the Gamma Knife.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A single dose of radiation cannot be used unless the adenoma is separated by several millimeters from the optic chiasm and optic nerves (to limit the exposure of the optic apparatus to less than 8 Gy), which would be severely damaged by such a high dose, resulting in blindness. In this situation,
         <strong>
          fractionated radiation
         </strong>
         must be used. (See
         <a class="medical medical_review" href="/z/d/html/86684.html" rel="external">
          "Radiation therapy of pituitary adenomas"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Fractionated radiation therapy
         </strong>
         – Fractionated radiation therapy is the delivery of radiation therapy in
         <strong>
          multiple
         </strong>
         , small, daily doses, usually five days a week for five to six weeks. This is the way RT is delivered for most other indications of radiation treatment.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Delivery systems
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The linear accelerator is the most common device used for RT, ie, for conventional radiation. Modifications have been made to deliver the radiation to the desired location and dose. (See
         <a class="medical medical_review" href="/z/d/html/86684.html" rel="external">
          "Radiation therapy of pituitary adenomas", section on 'Radiation delivery systems'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Gamma knife
         </strong>
         – Gamma Knife is an SRS treatment unit. Gamma radiation can be administered from a cobalt source but only as a single, large dose. Although this is called "Gamma Knife," there is no knife.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Proton therapy
         </strong>
         – High-energy proton particles
         <strong>
         </strong>
         can be administered from a cyclotron in either a single, large dose or multiple fractions.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Use of somatostatin agonists during RT
         </strong>
         – It was suggested in an earlier study that use of a somatostatin analog at the time of RT may limit its effectiveness, but this consideration has been refuted by subsequent studies [
         <a href="#rid88">
          88-90
         </a>
         ]. However, most clinicians do hold somatostatin agonists therapy while patients undergo RT.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H408870">
         <span class="h3">
          Efficacy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Few patients who undergo fractionated radiation achieve the current goal of therapy, ie, a basal serum GH concentration less than 1 mcg/L. Serum GH and IGF-1 concentrations decline on average approximately 20 percent per year, so that serum GH concentrations may not reach 5 to 10 mcg/L until 5 to 10 years or more after treatment if the initial value is very high [
         <a href="#rid91">
          91
         </a>
         ].
        </p>
        <p>
         By 20 years after treatment, up to 90 percent of patients have serum GH concentrations less than 5 mcg/L and 10 to 77 percent in different studies eventually achieved serum GH concentrations &lt;2.5 mcg/L (
         <a class="graphic graphic_table graphicRef55079" href="/z/d/graphic/55079.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid91">
          91-95
         </a>
         ]. In one series, as an example, only 5 of 30 patients (17 percent) followed for 10 or more years reached this goal [
         <a href="#rid96">
          96
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/86684.html" rel="external">
          "Radiation therapy of pituitary adenomas", section on 'Somatotroph adenomas (acromegaly)'
         </a>
         .)
        </p>
        <p>
         Normalization of the serum IGF-1 concentration occurs in approximately 55 to 70 percent of patients after 10 years, but the results vary among studies [
         <a href="#rid92">
          92-95
         </a>
         ].
        </p>
        <p>
         The efficacy of SRS appears to be similar to conventional RT. However, SRS may be more appealing because the treatment duration is shorter. In three studies of 35 to 96 acromegalic patients followed after gamma radiation [
         <a href="#rid97">
          97-99
         </a>
         ], cure rates (defined as normal age- and gender-adjusted IGF-1 concentrations and basal GH of &lt;2.5 mcg/L or post-glucose load values of &lt;1 mcg/L) were 46 to 60 percent in 5 to 10 years.
        </p>
        <p>
         As with fractionated radiation, cure rates due to single-dose radiation are higher the smaller the size of the adenoma and the lower the IGF-1 and GH.
        </p>
        <p class="headingAnchor" id="H1395545171">
         <span class="h3">
          Monitoring
         </span>
         <span class="headingEndMark">
          —
         </span>
         Because the full therapeutic effect of the RT may take many years and some patients may have limited response, it is important to perform annual reassessment of radiation efficacy.
        </p>
        <p>
         Once a normal serum IGF-1 level is achieved, medical therapy should be withdrawn annually for one to three months (depending on the specific drug) for reassessment of GH and IGF-1 levels.
        </p>
        <p>
         For patients who have undergone RT, we suggest annual pituitary hormone testing to detect hypopituitarism, which is common post-RT. We also evaluate for other delayed radiation effects such as cerebrovascular disease and cranial nerve abnormalities.
        </p>
        <p class="headingAnchor" id="H24">
         <span class="h3">
          Adverse effects
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hypopituitarism
         </strong>
         – Within 10 years, approximately 40 percent of patients treated with pituitary radiation develop deficiency of one or more pituitary hormones [
         <a href="#rid91">
          91,93
         </a>
         ], and the incidence continues to increase thereafter. Gonadotropin deficiency is most common, followed by corticotropin (ACTH) and then thyroid-stimulating hormone (TSH) deficiency. In the series of 884 patients, the percentage of patients with new hormone deficiencies 10 years after irradiation were 18, 15, and 27 percent for luteinizing hormone (LH)/follicle-stimulating hormone (FSH), ACTH, and TSH, respectively [
         <a href="#rid91">
          91
         </a>
         ]. A second study reported higher rates of hormone deficiencies, but patients had more severe disease (higher baseline serum GH concentrations) and received higher radiation doses (mean dose 52 Gy [
         <a href="#rid93">
          93
         </a>
         ] versus 45 Gy [
         <a href="#rid91">
          91
         </a>
         ]).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Hypopituitarism occurs after single-dose radiation, as it does with fractionated, in approximately 40 percent of those treated by both gamma and proton radiation [
         <a href="#rid97">
          97,98,100
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other complications
         </strong>
         – Other complications are cranial-nerve palsies, loss of vision, and memory deficits. All are rare and usually occur only when the dose is high [
         <a href="#rid93">
          93
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Second intracranial tumors have been reported in up to 1.7 percent of patients within the first 10 years after pituitary radiation, a considerably higher frequency (relative risk 16) than in normal subjects [
         <a href="#rid101">
          101,102
         </a>
         ]. The reported tumors include astrocytoma, glioblastoma, meningioma, and sarcoma [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Some evidence points to RT as being a significant independent determinant of overall mortality in acromegaly [
         <a href="#rid103">
          103,104
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1481729977">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/116763.html" rel="external">
          "Society guideline links: Diagnosis and treatment of acromegaly"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H32">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/16728.html" rel="external">
          "Patient education: Acromegaly (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/2166.html" rel="external">
          "Patient education: Acromegaly (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p>
         Patients can also get information about pituitary adenomas and their consequences from
         <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.pituitarysociety.org%2F&amp;token=vyLVZ0oKm7pgUFZXIAoElx6U8FBm8o88Voa9%2Fmhf3IdO%2BJSMKhYI2%2BGaUXykQfxC&amp;TOPIC_ID=6625" target="_blank">
          The Pituitary Society
         </a>
         and
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.endocrine.org%2F&amp;token=NyRkA1K%2BEfcjom0B%2BqrukuYPTJEm%2FHmxImWphO69X2360AzcGjMneuFZX35Bcion&amp;TOPIC_ID=6625" target="_blank">
          The Endocrine Society
         </a>
         .
        </p>
        <p class="headingAnchor" id="H33">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         A summary of treatment effects is provided in the table (
         <a class="graphic graphic_table graphicRef55079" href="/z/d/graphic/55079.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with a microadenoma, a macroadenoma that appears to be fully resectable, or a macroadenoma threatening or impairing vision, we recommend transsphenoidal surgery performed by a neurosurgeon with considerable experience in pituitary surgery (
         <a class="graphic graphic_algorithm graphicRef116165" href="/z/d/graphic/116165.html" rel="external">
          algorithm 1
         </a>
         ) (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). (See
         <a class="local">
          'Transsphenoidal surgery'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with an adenoma that does not appear to be fully resectable and for patients whose risk of surgery is great or who choose not to have surgery, we suggest primary therapy with a long-acting somatostatin analog (
         <a class="graphic graphic_algorithm graphicRef116165" href="/z/d/graphic/116165.html" rel="external">
          algorithm 1
         </a>
         ) (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). (See
         <a class="local">
          'Somatostatin analogs'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If transsphenoidal surgery results in normalization of serum insulin-like growth factor-1 (IGF-1) concentration, we suggest no further therapy, but we do suggest continued monitoring to detect a recurrence (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). (See
         <a class="local">
          'Transsphenoidal surgery'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If transsphenoidal surgery does not normalize the serum IGF-1 concentration, we suggest medical therapy with a long-acting somatostatin analog or growth hormone (GH) receptor antagonist. We suggest the dopamine agonist
         <a class="drug drug_general" data-topicid="8600" href="/z/d/drug information/8600.html" rel="external">
          cabergoline
         </a>
         for mild disease (
         <a class="graphic graphic_algorithm graphicRef116165" href="/z/d/graphic/116165.html" rel="external">
          algorithm 1
         </a>
         ) (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). (See
         <a class="local">
          'Additional therapy for residual disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If a somatostatin analog, with or without
         <a class="drug drug_general" data-topicid="8600" href="/z/d/drug information/8600.html" rel="external">
          cabergoline
         </a>
         , is ineffective, we suggest
         <a class="drug drug_general" data-topicid="10257" href="/z/d/drug information/10257.html" rel="external">
          pegvisomant
         </a>
         alone or in combination with the somatostatin analog (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). (See
         <a class="local">
          'Combination therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If adenoma size increases or GH/IGF-1 hypersecretion persists despite medical therapy (ie, somatostatin analog plus
         <a class="drug drug_general" data-topicid="10257" href="/z/d/drug information/10257.html" rel="external">
          pegvisomant
         </a>
         ), we suggest radiation therapy (RT) or repeat surgery (
         <a class="graphic graphic_algorithm graphicRef116165" href="/z/d/graphic/116165.html" rel="external">
          algorithm 1
         </a>
         ) (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). (See
         <a class="local">
          'Radiation therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p>
         For women who desire pregnancy:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pregnancy should be postponed, if possible, until GH and IGF-1 levels are controlled and no residual tumor mass is seen. We suggest controlling the serum GH and IGF-1 concentrations as tightly as possible before attempting pregnancy to minimize the risk of gestational diabetes mellitus (GDM) and gestational hypertension (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Pregnancy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We suggest stopping medical therapy when pregnancy is confirmed (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). The majority of adenomas do not grow during pregnancy. Short-acting
         <a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">
          octreotide
         </a>
         can be used during pregnancy, but
         <strong>
          only
         </strong>
         for control of headache and adenoma size. (See
         <a class="local">
          'Pregnancy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Visual fields should be monitored during pregnancy in women with macroadenomas starting at the end of the first trimester and every six weeks thereafter. Magnetic resonance imaging (MRI), without contrast, should be performed if visual field testing suggests a chiasmal lesion. If visual impairment due to a chiasmal lesion is confirmed, surgery may be necessary. (See
         <a class="local">
          'Pregnancy'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Melmed S. Acromegaly pathogenesis and treatment. J Clin Invest 2009; 119:3189.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Katznelson L, Laws ER Jr, Melmed S, et al. Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2014; 99:3933.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Freda PU, Post KD, Powell JS, Wardlaw SL. Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly. J Clin Endocrinol Metab 1998; 83:3808.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dimaraki EV, Jaffe CA, DeMott-Friberg R, et al. Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up. J Clin Endocrinol Metab 2002; 87:3537.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Puder JJ, Nilavar S, Post KD, Freda PU. Relationship between disease-related morbidity and biochemical markers of activity in patients with acromegaly. J Clin Endocrinol Metab 2005; 90:1972.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Melmed S. Medical progress: Acromegaly. N Engl J Med 2006; 355:2558.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Swearingen B, Barker FG 2nd, Katznelson L, et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 1998; 83:3419.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abosch A, Tyrrell JB, Lamborn KR, et al. Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results. J Clin Endocrinol Metab 1998; 83:3411.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Freda PU, Wardlaw SL, Post KD. Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly. J Neurosurg 1998; 89:353.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ronchi CL, Giavoli C, Ferrante E, et al. Prevalence of GH deficiency in cured acromegalic patients: impact of different previous treatments. Eur J Endocrinol 2009; 161:37.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ross DA, Wilson CB. Results of transsphenoidal microsurgery for growth hormone-secreting pituitary adenoma in a series of 214 patients. J Neurosurg 1988; 68:854.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ciric I, Ragin A, Baumgartner C, Pierce D. Complications of transsphenoidal surgery: results of a national survey, review of the literature, and personal experience. Neurosurgery 1997; 40:225.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barker FG 2nd, Klibanski A, Swearingen B. Transsphenoidal surgery for pituitary tumors in the United States, 1996-2000: mortality, morbidity, and the effects of hospital and surgeon volume. J Clin Endocrinol Metab 2003; 88:4709.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ahmed M, Kanaan I, Rifai A, et al. An unusual treatment-related complication in a patient with growth hormone-secreting pituitary tumor. J Clin Endocrinol Metab 1997; 82:2816.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fahlbusch R, Honegger J, Buchfelder M. Surgical management of acromegaly. Endocrinol Metab Clin North Am 1992; 21:669.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jenkins D, O'Brien I, Johnson A, et al. The Birmingham pituitary database: auditing the outcome of the treatment of acromegaly. Clin Endocrinol (Oxf) 1995; 43:517.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feelders RA, Bidlingmaier M, Strasburger CJ, et al. Postoperative evaluation of patients with acromegaly: clinical significance and timing of oral glucose tolerance testing and measurement of (free) insulin-like growth factor I, acid-labile subunit, and growth hormone-binding protein levels. J Clin Endocrinol Metab 2005; 90:6480.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sze L, Schmid C, Bloch KE, et al. Effect of transsphenoidal surgery on sleep apnoea in acromegaly. Eur J Endocrinol 2007; 156:321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Colao A, Marzullo P, Vallone G, et al. Reversibility of joint thickening in acromegalic patients: an ultrasonography study. J Clin Endocrinol Metab 1998; 83:2121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Broersen LHA, Zamanipoor Najafabadi AH, Pereira AM, et al. Improvement in Symptoms and Health-Related Quality of Life in Acromegaly Patients: A Systematic Review and Meta-Analysis. J Clin Endocrinol Metab 2021; 106:577.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wolters TLC, Roerink SHPP, Drenthen LCA, et al. The Course of Obstructive Sleep Apnea Syndrome in Patients With Acromegaly During Treatment. J Clin Endocrinol Metab 2020; 105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Biermasz NR, Pereira AM, Smit JW, et al. Morbidity after long-term remission for acromegaly: persisting joint-related complaints cause reduced quality of life. J Clin Endocrinol Metab 2005; 90:2731.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wexler T, Gunnell L, Omer Z, et al. Growth hormone deficiency is associated with decreased quality of life in patients with prior acromegaly. J Clin Endocrinol Metab 2009; 94:2471.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller KK, Wexler T, Fazeli P, et al. Growth hormone deficiency after treatment of acromegaly: a randomized, placebo-controlled study of growth hormone replacement. J Clin Endocrinol Metab 2010; 95:567.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Norrman LL, Johannsson G, Sunnerhagen KS, Svensson J. Baseline characteristics and the effects of two years of growth hormone (GH) replacement therapy in adults with GH deficiency previously treated for acromegaly. J Clin Endocrinol Metab 2008; 93:2531.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grynberg M, Salenave S, Young J, Chanson P. Female gonadal function before and after treatment of acromegaly. J Clin Endocrinol Metab 2010; 95:4518.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maffei P, Tamagno G, Nardelli GB, et al. Effects of octreotide exposure during pregnancy in acromegaly. Clin Endocrinol (Oxf) 2010; 72:668.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cheng S, Grasso L, Martinez-Orozco JA, et al. Pregnancy in acromegaly: experience from two referral centers and systematic review of the literature. Clin Endocrinol (Oxf) 2012; 76:264.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jallad RS, Shimon I, Fraenkel M, et al. Outcome of pregnancies in a large cohort of women with acromegaly. Clin Endocrinol (Oxf) 2018; 88:896.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frankenne F, Closset J, Gomez F, et al. The physiology of growth hormones (GHs) in pregnant women and partial characterization of the placental GH variant. J Clin Endocrinol Metab 1988; 66:1171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eriksson L, Frankenne F, Edèn S, et al. Growth hormone 24-h serum profiles during pregnancy--lack of pulsatility for the secretion of the placental variant. Br J Obstet Gynaecol 1989; 96:949.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caron P, Broussaud S, Bertherat J, et al. Acromegaly and pregnancy: a retrospective multicenter study of 59 pregnancies in 46 women. J Clin Endocrinol Metab 2010; 95:4680.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Starke RM, Raper DM, Payne SC, et al. Endoscopic vs microsurgical transsphenoidal surgery for acromegaly: outcomes in a concurrent series of patients using modern criteria for remission. J Clin Endocrinol Metab 2013; 98:3190.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Babu H, Ortega A, Nuno M, et al. Long-Term Endocrine Outcomes Following Endoscopic Endonasal Transsphenoidal Surgery for Acromegaly and Associated Prognostic Factors. Neurosurgery 2017; 81:357.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ben-Shlomo A, Melmed S. Clinical review 154: The role of pharmacotherapy in perioperative management of patients with acromegaly. J Clin Endocrinol Metab 2003; 88:963.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jane JA Jr, Starke RM, Elzoghby MA, et al. Endoscopic transsphenoidal surgery for acromegaly: remission using modern criteria, complications, and predictors of outcome. J Clin Endocrinol Metab 2011; 96:2732.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hofstetter CP, Mannaa RH, Mubita L, et al. Endoscopic endonasal transsphenoidal surgery for growth hormone-secreting pituitary adenomas. Neurosurg Focus 2010; 29:E6.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kreutzer J, Vance ML, Lopes MB, Laws ER Jr. Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria. J Clin Endocrinol Metab 2001; 86:4072.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Biermasz NR, van Dulken H, Roelfsema F. Ten-year follow-up results of transsphenoidal microsurgery in acromegaly. J Clin Endocrinol Metab 2000; 85:4596.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Freda PU, Nuruzzaman AT, Reyes CM, et al. Significance of "abnormal" nadir growth hormone levels after oral glucose in postoperative patients with acromegaly in remission with normal insulin-like growth factor-I levels. J Clin Endocrinol Metab 2004; 89:495.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cozzi R, Montini M, Attanasio R, et al. Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. J Clin Endocrinol Metab 2006; 91:1397.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shimon I, Yan X, Taylor JE, et al. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors. J Clin Invest 1997; 100:2386.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taboada GF, Luque RM, Neto LV, et al. Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR. Eur J Endocrinol 2008; 158:295.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fougner SL, Casar-Borota O, Heck A, et al. Adenoma granulation pattern correlates with clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly. Clin Endocrinol (Oxf) 2012; 76:96.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Melmed S. New therapeutic agents for acromegaly. Nat Rev Endocrinol 2016; 12:90.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thapar K, Kovacs KT, Stefaneanu L, et al. Antiproliferative effect of the somatostatin analogue octreotide on growth hormone-producing pituitary tumors: results of a multicenter randomized trial. Mayo Clin Proc 1997; 72:893.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Losa M, Ciccarelli E, Mortini P, et al. Effects of octreotide treatment on the proliferation and apoptotic index of GH-secreting pituitary adenomas. J Clin Endocrinol Metab 2001; 86:5194.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caron P, Beckers A, Cullen DR, et al. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly. J Clin Endocrinol Metab 2002; 87:99.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giustina A, Mazziotti G, Cannavò S, et al. High-Dose and High-Frequency Lanreotide Autogel in Acromegaly: A Randomized, Multicenter Study. J Clin Endocrinol Metab 2017; 102:2454.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giustina A, Bonadonna S, Bugari G, et al. High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial. Eur J Endocrinol 2009; 161:331.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murray RD, Melmed S. A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. J Clin Endocrinol Metab 2008; 93:2957.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Larkin S, Reddy R, Karavitaki N, et al. Granulation pattern, but not GSP or GHR mutation, is associated with clinical characteristics in somatostatin-naive patients with somatotroph adenomas. Eur J Endocrinol 2013; 168:491.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kiseljak-Vassiliades K, Shafi S, Kerr JM, et al. Clinical implications of growth hormone-secreting tumor subtypes. Endocrine 2012; 42:18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heck A, Ringstad G, Fougner SL, et al. Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly. Clin Endocrinol (Oxf) 2012; 77:72.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Puig-Domingo M, Resmini E, Gomez-Anson B, et al. Magnetic resonance imaging as a predictor of response to somatostatin analogs in acromegaly after surgical failure. J Clin Endocrinol Metab 2010; 95:4973.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bevan JS, Atkin SL, Atkinson AB, et al. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. J Clin Endocrinol Metab 2002; 87:4554.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Freda PU. Somatostatin analogs in acromegaly. J Clin Endocrinol Metab 2002; 87:3013.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neggers SJ, Franck SE, de Rooij FW, et al. Long-term efficacy and safety of pegvisomant in combination with long-acting somatostatin analogs in acromegaly. J Clin Endocrinol Metab 2014; 99:3644.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 2004; 25:102.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grunstein RR, Ho KK, Sullivan CE. Effect of octreotide, a somatostatin analog, on sleep apnea in patients with acromegaly. Ann Intern Med 1994; 121:478.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Herrmann BL, Wessendorf TE, Ajaj W, et al. Effects of octreotide on sleep apnoea and tongue volume (magnetic resonance imaging) in patients with acromegaly. Eur J Endocrinol 2004; 151:309.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lim MJ, Barkan AL, Buda AJ. Rapid reduction of left ventricular hypertrophy in acromegaly after suppression of growth hormone hypersecretion. Ann Intern Med 1992; 117:719.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Colao A, Cuocolo A, Marzullo P, et al. Effects of 1-year treatment with octreotide on cardiac performance in patients with acromegaly. J Clin Endocrinol Metab 1999; 84:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maison P, Tropeano AI, Macquin-Mavier I, et al. Impact of somatostatin analogs on the heart in acromegaly: a metaanalysis. J Clin Endocrinol Metab 2007; 92:1743.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Melmed S, Sternberg R, Cook D, et al. A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J Clin Endocrinol Metab 2005; 90:4405.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Colao A, Pivonello R, Auriemma RS, et al. Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients. J Clin Endocrinol Metab 2006; 91:2112.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ. Octreotide. N Engl J Med 1996; 334:246.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grasso LF, Auriemma RS, Pivonello R, Colao A. Adverse events associated with somatostatin analogs in acromegaly. Expert Opin Drug Saf 2015; 14:1213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mazziotti G, Floriani I, Bonadonna S, et al. Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies. J Clin Endocrinol Metab 2009; 94:1500.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Colao A, Bronstein MD, Freda P, et al. Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J Clin Endocrinol Metab 2014; 99:791.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fleseriu M, Biller BMK, Freda PU, et al. A Pituitary Society update to acromegaly management guidelines. Pituitary 2021; 24:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Melmed S, Popovic V, Bidlingmaier M, et al. Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial. J Clin Endocrinol Metab 2015; 100:1699.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pradhananga S, Wilkinson I, Ross RJ. Pegvisomant: structure and function. J Mol Endocrinol 2002; 29:11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jehle S, Reyes CM, Sundeen RE, Freda PU. Alternate-day administration of pegvisomant maintains normal serum insulin-like growth factor-I levels in patients with acromegaly. J Clin Endocrinol Metab 2005; 90:1588.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parkinson C, Burman P, Messig M, Trainer PJ. Gender, body weight, disease activity, and previous radiotherapy influence the response to pegvisomant. J Clin Endocrinol Metab 2007; 92:190.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trainer PJ, Drake WM, Katznelson L, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 2000; 342:1171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Biering H, Saller B, Bauditz J, et al. Elevated transaminases during medical treatment of acromegaly: a review of the German pegvisomant surveillance experience and a report of a patient with histologically proven chronic mild active hepatitis. Eur J Endocrinol 2006; 154:213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van der Lely AJ, Biller BM, Brue T, et al. Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY. J Clin Endocrinol Metab 2012; 97:1589.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buhk JH, Jung S, Psychogios MN, et al. Tumor volume of growth hormone-secreting pituitary adenomas during treatment with pegvisomant: a prospective multicenter study. J Clin Endocrinol Metab 2010; 95:552.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trainer PJ. ACROSTUDY: the first 5 years. Eur J Endocrinol 2009; 161 Suppl 1:S19.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bonert VS, Kennedy L, Petersenn S, et al. Lipodystrophy in patients with acromegaly receiving pegvisomant. J Clin Endocrinol Metab 2008; 93:3515.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feenstra J, de Herder WW, ten Have SM, et al. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet 2005; 365:1644.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trainer PJ, Ezzat S, D'Souza GA, et al. A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly. Clin Endocrinol (Oxf) 2009; 71:549.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Madsen M, Poulsen PL, Orskov H, et al. Cotreatment with pegvisomant and a somatostatin analog (SA) in SA-responsive acromegalic patients. J Clin Endocrinol Metab 2011; 96:2405.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sandret L, Maison P, Chanson P. Place of cabergoline in acromegaly: a meta-analysis. J Clin Endocrinol Metab 2011; 96:1327.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abs R, Verhelst J, Maiter D, et al. Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab 1998; 83:374.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loeffler JS, Shih HA. Radiation therapy in the management of pituitary adenomas. J Clin Endocrinol Metab 2011; 96:1992.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Landolt AM, Haller D, Lomax N, et al. Octreotide may act as a radioprotective agent in acromegaly. J Clin Endocrinol Metab 2000; 85:1287.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Castinetti F, Taieb D, Kuhn JM, et al. Outcome of gamma knife radiosurgery in 82 patients with acromegaly: correlation with initial hypersecretion. J Clin Endocrinol Metab 2005; 90:4483.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pollock BE, Jacob JT, Brown PD, Nippoldt TB. Radiosurgery of growth hormone-producing pituitary adenomas: factors associated with biochemical remission. J Neurosurg 2007; 106:833.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jenkins PJ, Bates P, Carson MN, et al. Conventional pituitary irradiation is effective in lowering serum growth hormone and insulin-like growth factor-I in patients with acromegaly. J Clin Endocrinol Metab 2006; 91:1239.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Powell JS, Wardlaw SL, Post KD, Freda PU. Outcome of radiotherapy for acromegaly using normalization of insulin-like growth factor I to define cure. J Clin Endocrinol Metab 2000; 85:2068.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barrande G, Pittino-Lungo M, Coste J, et al. Hormonal and metabolic effects of radiotherapy in acromegaly: long-term results in 128 patients followed in a single center. J Clin Endocrinol Metab 2000; 85:3779.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cozzi R, Barausse M, Asnaghi D, et al. Failure of radiotherapy in acromegaly. Eur J Endocrinol 2001; 145:717.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Epaminonda P, Porretti S, Cappiello V, et al. Efficacy of radiotherapy in normalizing serum IGF-I, acid-labile subunit (ALS) and IGFBP-3 levels in acromegaly. Clin Endocrinol (Oxf) 2001; 55:183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thalassinos NC, Tsagarakis S, Ioannides G, et al. Megavoltage pituitary irradiation lowers but seldom leads to safe GH levels in acromegaly: a long-term follow-up study. Eur J Endocrinol 1998; 138:160.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jezková J, Marek J, Hána V, et al. Gamma knife radiosurgery for acromegaly--long-term experience. Clin Endocrinol (Oxf) 2006; 64:588.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ronchi CL, Attanasio R, Verrua E, et al. Efficacy and tolerability of gamma knife radiosurgery in acromegaly: a 10-year follow-up study. Clin Endocrinol (Oxf) 2009; 71:846.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee CC, Vance ML, Xu Z, et al. Stereotactic radiosurgery for acromegaly. J Clin Endocrinol Metab 2014; 99:1273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Petit JH, Biller BM, Coen JJ, et al. Proton stereotactic radiosurgery in management of persistent acromegaly. Endocr Pract 2007; 13:726.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brada M, Ford D, Ashley S, et al. Risk of second brain tumour after conservative surgery and radiotherapy for pituitary adenoma. BMJ 1992; 304:1343.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsang RW, Laperriere NJ, Simpson WJ, et al. Glioma arising after radiation therapy for pituitary adenoma. A report of four patients and estimation of risk. Cancer 1993; 72:2227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sherlock M, Reulen RC, Alonso AA, et al. ACTH deficiency, higher doses of hydrocortisone replacement, and radiotherapy are independent predictors of mortality in patients with acromegaly. J Clin Endocrinol Metab 2009; 94:4216.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ayuk J, Clayton RN, Holder G, et al. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J Clin Endocrinol Metab 2004; 89:1613.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 6625 Version 32.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19884662" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Acromegaly pathogenesis and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25356808" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Acromegaly: an endocrine society clinical practice guideline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9814451" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12161471" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15634715" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Relationship between disease-related morbidity and biochemical markers of activity in patients with acromegaly.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17167139" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Medical progress: Acromegaly.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9768641" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9768640" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9724106" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19351744" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Prevalence of GH deficiency in cured acromegalic patients: impact of different previous treatments.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3373281" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Results of transsphenoidal microsurgery for growth hormone-secreting pituitary adenoma in a series of 214 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9007854" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Complications of transsphenoidal surgery: results of a national survey, review of the literature, and personal experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14557445" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Transsphenoidal surgery for pituitary tumors in the United States, 1996-2000: mortality, morbidity, and the effects of hospital and surgeon volume.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9284702" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : An unusual treatment-related complication in a patient with growth hormone-secreting pituitary tumor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1521518" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Surgical management of acromegaly.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8548933" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : The Birmingham pituitary database: auditing the outcome of the treatment of acromegaly.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16159936" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Postoperative evaluation of patients with acromegaly: clinical significance and timing of oral glucose tolerance testing and measurement of (free) insulin-like growth factor I, acid-labile subunit, and growth hormone-binding protein levels.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17322492" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Effect of transsphenoidal surgery on sleep apnoea in acromegaly.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9626149" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Reversibility of joint thickening in acromegalic patients: an ultrasonography study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33245343" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Improvement in Symptoms and Health-Related Quality of Life in Acromegaly Patients: A Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31612224" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : The Course of Obstructive Sleep Apnea Syndrome in Patients With Acromegaly During Treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15741257" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Morbidity after long-term remission for acromegaly: persisting joint-related complaints cause reduced quality of life.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19366847" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Growth hormone deficiency is associated with decreased quality of life in patients with prior acromegaly.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20061426" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Growth hormone deficiency after treatment of acromegaly: a randomized, placebo-controlled study of growth hormone replacement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18397981" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Baseline characteristics and the effects of two years of growth hormone (GH) replacement therapy in adults with GH deficiency previously treated for acromegaly.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20660045" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Female gonadal function before and after treatment of acromegaly.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19769624" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Effects of octreotide exposure during pregnancy in acromegaly.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21777265" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Pregnancy in acromegaly: experience from two referral centers and systematic review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29574986" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Outcome of pregnancies in a large cohort of women with acromegaly.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3372680" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : The physiology of growth hormones (GHs) in pregnant women and partial characterization of the placental GH variant.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2775694" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Growth hormone 24-h serum profiles during pregnancy--lack of pulsatility for the secretion of the placental variant.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20660047" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Acromegaly and pregnancy: a retrospective multicenter study of 59 pregnancies in 46 women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23737543" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Endoscopic vs microsurgical transsphenoidal surgery for acromegaly: outcomes in a concurrent series of patients using modern criteria for remission.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28368500" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Long-Term Endocrine Outcomes Following Endoscopic Endonasal Transsphenoidal Surgery for Acromegaly and Associated Prognostic Factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12629068" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Clinical review 154: The role of pharmacotherapy in perioperative management of patients with acromegaly.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21715544" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Endoscopic transsphenoidal surgery for acromegaly: remission using modern criteria, complications, and predictors of outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20887131" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Endoscopic endonasal transsphenoidal surgery for growth hormone-secreting pituitary adenomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11549628" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11134114" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Ten-year follow-up results of transsphenoidal microsurgery in acromegaly.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14764751" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Significance of "abnormal" nadir growth hormone levels after oral glucose in postoperative patients with acromegaly in remission with normal insulin-like growth factor-I levels.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16449332" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9410919" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18299461" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21722151" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Adenoma granulation pattern correlates with clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26610414" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : New therapeutic agents for acromegaly.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9379690" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Antiproliferative effect of the somatostatin analogue octreotide on growth hormone-producing pituitary tumors: results of a multicenter randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11701676" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Effects of octreotide treatment on the proliferation and apoptotic index of GH-secreting pituitary adenomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11788630" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28419317" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : High-Dose and High-Frequency Lanreotide Autogel in Acromegaly: A Randomized, Multicenter Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19465485" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18477663" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23288882" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Granulation pattern, but not GSP or GHR mutation, is associated with clinical characteristics in somatostatin-naive patients with somatotroph adenomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22434413" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Clinical implications of growth hormone-secreting tumor subtypes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22066905" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20739382" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Magnetic resonance imaging as a predictor of response to somatostatin analogs in acromegaly after surgical failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12364434" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12107192" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Somatostatin analogs in acromegaly.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24937542" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Long-term efficacy and safety of pegvisomant in combination with long-acting somatostatin analogs in acromegaly.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14769829" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Systemic complications of acromegaly: epidemiology, pathogenesis, and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8067645" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Effect of octreotide, a somatostatin analog, on sleep apnea in patients with acromegaly.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15362959" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Effects of octreotide on sleep apnoea and tongue volume (magnetic resonance imaging) in patients with acromegaly.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1416573" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Rapid reduction of left ventricular hypertrophy in acromegaly after suppression of growth hormone hypersecretion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9920056" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Effects of 1-year treatment with octreotide on cardiac performance in patients with acromegaly.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17311857" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Impact of somatostatin analogs on the heart in acromegaly: a metaanalysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15827109" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16537687" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8532003" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Octreotide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26184380" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Adverse events associated with somatostatin analogs in acromegaly.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19208728" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24423324" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Pasireotide versus octreotide in acromegaly: a head-to-head superiority study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33079318" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : A Pituitary Society update to acromegaly management guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25664604" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12200225" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Pegvisomant: structure and function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15585549" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Alternate-day administration of pegvisomant maintains normal serum insulin-like growth factor-I levels in patients with acromegaly.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17077131" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Gender, body weight, disease activity, and previous radiotherapy influence the response to pegvisomant.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10770982" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16452533" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Elevated transaminases during medical treatment of acromegaly: a review of the German pegvisomant surveillance experience and a report of a patient with histologically proven chronic mild active hepatitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22362824" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19965922" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Tumor volume of growth hormone-secreting pituitary adenomas during treatment with pegvisomant: a prospective multicenter study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19684052" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : ACROSTUDY: the first 5 years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18611977" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Lipodystrophy in patients with acromegaly receiving pegvisomant.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15885297" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19438906" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21632808" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Cotreatment with pegvisomant and a somatostatin analog (SA) in SA-responsive acromegalic patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21325455" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Place of cabergoline in acromegaly: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9467544" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Cabergoline in the treatment of acromegaly: a study in 64 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21525155" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Radiation therapy in the management of pituitary adenomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10720077" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Octreotide may act as a radioprotective agent in acromegaly.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15899958" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Outcome of gamma knife radiosurgery in 82 patients with acromegaly: correlation with initial hypersecretion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17542527" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Radiosurgery of growth hormone-producing pituitary adenomas: factors associated with biochemical remission.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16403824" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Conventional pituitary irradiation is effective in lowering serum growth hormone and insulin-like growth factor-I in patients with acromegaly.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10843197" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Outcome of radiotherapy for acromegaly using normalization of insulin-like growth factor I to define cure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11061538" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Hormonal and metabolic effects of radiotherapy in acromegaly: long-term results in 128 patients followed in a single center.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11720896" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Failure of radiotherapy in acromegaly.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11531924" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Efficacy of radiotherapy in normalizing serum IGF-I, acid-labile subunit (ALS) and IGFBP-3 levels in acromegaly.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9506859" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Megavoltage pituitary irradiation lowers but seldom leads to safe GH levels in acromegaly: a long-term follow-up study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16649981" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Gamma knife radiosurgery for acromegaly--long-term experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19508606" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Efficacy and tolerability of gamma knife radiosurgery in acromegaly: a 10-year follow-up study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24471574" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Stereotactic radiosurgery for acromegaly.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18194929" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Proton stereotactic radiosurgery in management of persistent acromegaly.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1611331" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Risk of second brain tumour after conservative surgery and radiotherapy for pituitary adenoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8374881" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Glioma arising after radiation therapy for pituitary adenoma. A report of four patients and estimation of risk.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19808848" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : ACTH deficiency, higher doses of hydrocortisone replacement, and radiotherapy are independent predictors of mortality in patients with acromegaly.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15070920" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
